Genetic factors play a role in at least 10% of adult cases of kidney disease and up to 70% of cases in children. In this test specific episode of the "Answers From the Lab" podcast, Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive and accurate results for optimal patient care.

"Our tests are among the most comprehensive diagnostic tests available. They utilize next generation sequencing for maximum depth of coverage and the highest possible detection rates across 302 genes, including technically challenging genes," Dr. Baudhin says.

The testing can identify potential underlying genetic causes of kidney disease and the specific type of kidney disease a patient has. "The results can then be used to guide treatment, inform prognosis and assess family members' risk," Thoreson says.

Unlike competitors' screening tests, Mayo Clinic Laboratories' panels are diagnostic. "You can trust them to identify an actual medical condition," Dr. Baudhin says. "Screening tests require clinical confirmation. The actual implications of the results are harder to understand."

Listen to learn more about Mayo Clinic Laboratories' renal genetics panel.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less